• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    PYC Therapeutics (ASX:PYC) Names New CFO As Investors Weigh A Pricey Valuation

    Simply Wall St·07/11/2026 23:20:22
    Listen to the news

    PYC Therapeutics (ASX:PYC) drew investor attention after appointing Thomas Ulmer as Chief Financial Officer, adding biotechnology and pharmaceuticals finance experience that includes guiding Immatics N.V. through its listing as a US biotechnology company.

    See our latest analysis for PYC Therapeutics.

    Beyond the CFO appointment, PYC Therapeutics has seen a 31.78% 1 month share price return and a 32.34% 3 month share price return, while its 3 year total shareholder return of 131.44% points to strong longer term momentum compared with more mixed year to date moves.

    If you are looking for other healthcare and biotech related ideas after PYC Therapeutics, it could be worth scanning 8 healthcare AI stocks.

    After a strong 3 month share price move and a long term total return that already looks substantial, the key question for PYC Therapeutics now is whether meaningful upside still lies ahead or whether most of the easy gains are already behind it.

    Preferred Price to Book Multiple of 10.4x: Is it justified?

    PYC Therapeutics currently trades on a P/B ratio of 10.4x, which looks demanding when set against its last close of A$1.56 and the sector backdrop.

    P/B compares the market value of a company with its net assets. A higher figure usually reflects strong expectations around future returns or valuable intangible assets that are not fully captured on the balance sheet. For PYC Therapeutics, this sits alongside an unprofitable profile and a reported loss of A$47.56m on revenue of A$20.56m, with analysts expecting revenue to decline each year and profits to remain negative over the next 3 years.

    Against that context, a 10.4x P/B looks rich when set against both the Australian biotechs industry average of 2.5x and a peer average closer to 9.1x. Those comparisons indicate the market is assigning PYC Therapeutics a premium valuation relative to assets, at a time when the company is not generating profits and forecasts do not point to a near term shift into profitability.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 10.4x (OVERVALUED)

    However, PYC Therapeutics still faces risks if clinical trial outcomes disappoint or if revenue, which currently sits at A$20.56m, comes under further pressure.

    Find out about the key risks to this PYC Therapeutics narrative.

    Next Steps

    If this all feels finely balanced for PYC Therapeutics, use that urgency to review the details yourself and see what stands out in the risk profile, starting with these 2 important warning signs.

    Looking for more investment ideas beyond PYC Therapeutics?

    If you are serious about building a stronger portfolio, do not stop at PYC Therapeutics. Use these focused stock ideas to keep your watchlist working harder.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.